These authors reported a global response rate of 28% in NRAS mutant MM versus 16% in MM of other genotypes (p = 0.04), with a clinical benefit of 50% versus 31% (p < 0.01) and a PFS of 4.1, versus. The gene discussed is NRAS; the disease is Miyoshi myopathy.